KRASG12C‐inhibitor‐based combination therapies for pancreatic cancer: insights from drug screening

Pancreatic ductal adenocarcinoma (PDAC) has limited treatment options, emphasizing the urgent need for effective therapies. The predominant driver in PDAC is mutated KRAS proto‐oncogene, KRA, present in 90% of patients. The emergence of direct KRAS inhibitors presents a promising avenue for treatmen...

Full description

Saved in:

Bibliographic Details
Main Authors:	Constanza Tapia Contreras, Jonas Dominik Falke, Dana‐Magdalena Seifert, Carolin Schneider, Lukas Krauß, Xin Fang, Denise Müller, Engin Demirdizen, Melanie Spitzner, Tiago De Oliveira, Christian Schneeweis, Jochen Gaedcke, Silke Kaulfuß, Kimia Mirzakhani, Bernd Wollnik, Karly Conrads, Tim Beißbarth, Gabriela Salinas, Jonas Hügel, Nils Beyer, Sophia Rheinländer, Ulrich Sax, Matthias Wirth, Lena‐Christin Conradi, Maximilian Reichert, Volker Ellenrieder, Philipp Ströbel, Michael Ghadimi, Marian Grade, Dieter Saur, Elisabeth Hessmann, Günter Schneider
Format:	Article
Language:	English
Published:	Wiley 2025-02-01
Series:	Molecular Oncology
Subjects:	KRASG12C pancreatic cancer SHP2 SOS1
Online Access:	https://doi.org/10.1002/1878-0261.13725
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

KRASG12C‐inhibitor‐based combination therapies for pancreatic cancer: insights from drug screening

Similar Items